Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, West Huaihai Road 241, Shanghai 200030, China.
School of Biomedical Engineering and Med-X Research Institute, Shanghai Jiao Tong University, Huashan Road 1954, Shanghai 200030, China.
Clin Exp Immunol. 2022 Jun 23;208(3):316-322. doi: 10.1093/cei/uxac045.
Immune Check-Point Inhibitors (ICIs) have shown remarkable promise in treating tumors, including non-small cell lung cancer (NSCLC). Nevertheless, the treatment response rate is low. Studies have found that the high expression of exosomal PD-L1 is one of the reasons for the low treatment response. Therefore, this study focused on the relationship between the exosomal PD-L1 and the clinical response to immunotherapy in NSCLC patients to evaluate whether it could be used as a biomarker to predict the efficacy of ICIs. In this study, clinical information and blood samples of 149 NSCLC patients receiving ICIs were collected. The expression level of exosomal PD-L1 was detected by enzyme-linked immunosorbent assay method, and the relationship between exosomal PD-L1 and the efficacy of ICIs was explored. Overall, our study found that the expression level of exosomal PD-L1 was lower at pre-treatment, or the max fold increasing change higher at 3-6 weeks had a higher disease control rate and longer progression-free survival. It revealed that the exosomal PD-L1 was associated with the treatment response of patients using ICIs and provided a new tool for the evaluation of clinical efficacy of lung cancer immunotherapy.
免疫检查点抑制剂 (ICIs) 在治疗肿瘤方面表现出了显著的疗效，包括非小细胞肺癌 (NSCLC)。然而，治疗反应率较低。研究发现，外泌体 PD-L1 的高表达是治疗反应率低的原因之一。因此，本研究聚焦于 NSCLC 患者外泌体 PD-L1 与免疫治疗临床反应的关系，以评估其是否可作为预测 ICI 疗效的生物标志物。在这项研究中，收集了 149 名接受 ICI 治疗的 NSCLC 患者的临床信息和血液样本。采用酶联免疫吸附试验方法检测外泌体 PD-L1 的表达水平，探讨外泌体 PD-L1 与 ICI 疗效的关系。总的来说，我们的研究发现，治疗前外泌体 PD-L1 的表达水平较低，或 3-6 周时最大倍数增加变化较高的患者，疾病控制率更高，无进展生存期更长。这表明外泌体 PD-L1 与患者使用 ICI 的治疗反应相关，并为评估肺癌免疫治疗的临床疗效提供了一种新的工具。
